Michael Craig Miller

23.5k total citations · 10 hit papers
153 papers, 18.4k citations indexed

About

Michael Craig Miller is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Michael Craig Miller has authored 153 papers receiving a total of 18.4k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Pulmonary and Respiratory Medicine, 48 papers in Oncology and 39 papers in Cancer Research. Recurrent topics in Michael Craig Miller's work include Prostate Cancer Treatment and Research (39 papers), Cancer Cells and Metastasis (37 papers) and Prostate Cancer Diagnosis and Treatment (31 papers). Michael Craig Miller is often cited by papers focused on Prostate Cancer Treatment and Research (39 papers), Cancer Cells and Metastasis (37 papers) and Prostate Cancer Diagnosis and Treatment (31 papers). Michael Craig Miller collaborates with scholars based in United States, Netherlands and United Kingdom. Michael Craig Miller's co-authors include Leon W.M.M. Terstappen, Gerald V. Doyle, W. Jeffrey Allard, Jeri Matera, Massimo Cristofanilli, Daniel F. Hayes, G. Thomas Budd, Alison Stopeck, Matthew J. Ellis and James M. Reuben and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Michael Craig Miller

143 papers receiving 17.9k citations

Hit Papers

Circulating Tumor Cells, ... 2004 2026 2011 2018 2004 2004 2008 2008 2005 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
    2004 3.5k citations Jeri Matera, Michael Craig Miller et al. profile →
  2. Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases
    2004 2.0k citations W. Jeffrey Allard, Jeri Matera et al. Clinical Cancer Research profile →
  3. Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
    2008 1.7k citations Johann S. de Bono, Howard I. Scher et al. Clinical Cancer Research profile →
  4. Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
    2008 1.5k citations Steven J. Cohen, Cornelis J.A. Punt et al. Journal of Clinical Oncology profile →
  5. Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
    2005 857 citations Daniel F. Hayes, Gerald V. Doyle et al. Journal of Clinical Oncology profile →
  6. Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival
    2006 808 citations Daniel F. Hayes, Michael Craig Miller et al. Clinical Cancer Research profile →
  7. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
    2008 641 citations Richard G. Moore, Amy Brown et al. Gynecologic Oncology profile →
  8. Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer
    2009 609 citations Michael Craig Miller, Gerald V. Doyle et al. profile →
  9. Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer
    2006 594 citations Michael Craig Miller, Jeri Matera et al. Clinical Cancer Research profile →
  10. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass
    2007 532 citations Richard G. Moore, Amy Brown et al. Gynecologic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Craig Miller United States 45 11.5k 8.3k 5.4k 3.5k 3.5k 153 18.4k
Tanja Fehm Germany 60 10.6k 0.9× 8.2k 1.0× 3.2k 0.6× 1.4k 0.4× 4.3k 1.2× 597 16.9k
W. Jeffrey Allard United States 25 6.4k 0.6× 4.5k 0.5× 2.9k 0.5× 2.1k 0.6× 3.3k 1.0× 50 11.8k
Markus Wallwiener Germany 38 20.1k 1.7× 6.2k 0.8× 7.0k 1.3× 1.1k 0.3× 7.8k 2.2× 279 30.8k
Sara Y. Brucker Germany 31 18.4k 1.6× 4.9k 0.6× 6.6k 1.2× 868 0.2× 7.2k 2.1× 130 27.9k
P. J. van Diest Netherlands 75 8.3k 0.7× 8.8k 1.1× 3.1k 0.6× 1.3k 0.4× 7.5k 2.2× 669 25.4k
Daphne W. Bell United States 49 14.5k 1.3× 6.8k 0.8× 13.5k 2.5× 2.3k 0.6× 16.5k 4.7× 86 32.2k
Luis A. Díaz United States 84 14.6k 1.3× 13.9k 1.7× 6.5k 1.2× 1.2k 0.3× 13.1k 3.7× 419 40.3k
Florin‐Andrei Taran Germany 23 18.6k 1.6× 4.9k 0.6× 6.6k 1.2× 792 0.2× 6.8k 2.0× 77 26.3k
Eva‐Maria Grischke Germany 24 20.6k 1.8× 5.5k 0.7× 8.4k 1.5× 1.3k 0.4× 7.6k 2.2× 126 29.4k
Hitoshi Tsuda Japan 73 7.9k 0.7× 5.7k 0.7× 4.2k 0.8× 483 0.1× 7.2k 2.0× 610 20.2k

Countries citing papers authored by Michael Craig Miller

Since Specialization
Citations

This map shows the geographic impact of Michael Craig Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Craig Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Craig Miller more than expected).

Fields of papers citing papers by Michael Craig Miller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Craig Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Craig Miller. The network helps show where Michael Craig Miller may publish in the future.

Co-authorship network of co-authors of Michael Craig Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Craig Miller. A scholar is included among the top collaborators of Michael Craig Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Craig Miller. Michael Craig Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shaw, Reid, et al.. (2022). Stacking Machine Learning Algorithms for Biomarker-Based Preoperative Diagnosis of a Pelvic Mass. Cancers. 14(5). 1291–1291. 10 indexed citations
2.
Joerger, Markus, Stefanie Kraff, Ulrich Jaehde, et al.. (2017). Validation of a Commercial Assay and Decision Support Tool for Routine Paclitaxel Therapeutic Drug Monitoring (TDM). Therapeutic Drug Monitoring. 39(6). 617–624. 13 indexed citations
3.
Zhu, Guangjing, Zhi Liu, Jonathan I. Epstein, et al.. (2015). A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype. Cancer Epidemiology Biomarkers & Prevention. 24(12). 1864–1872. 13 indexed citations
4.
Paoletti, Costanza, Maria C. Muñiz, Dafydd G. Thomas, et al.. (2014). Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor–Positive Breast Cancer. Clinical Cancer Research. 21(11). 2487–2498. 104 indexed citations
5.
Miller, Michael Craig. (2011). Understanding grief and loss. Bereavement shares much in common with depression.. PubMed. 28(6). 1–1. 2 indexed citations
6.
Holcomb, Kevin, Zivjena Vucetic, Michael Craig Miller, & Robert C. Knapp. (2011). Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. American Journal of Obstetrics and Gynecology. 205(4). 358.e1–358.e6. 92 indexed citations
7.
Moore, Richard G., Michael Craig Miller, Elizabeth Eklund, et al.. (2011). Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. American Journal of Obstetrics and Gynecology. 206(4). 349.e1–349.e7. 124 indexed citations
8.
Isharwal, Sumit, Michael Craig Miller, Jonathan I. Epstein, et al.. (2009). DNA Ploidy as Surrogate for Biopsy Gleason Score for Preoperative Organ Versus Nonorgan-confined Prostate Cancer Prediction. Urology. 73(5). 1092–1097. 12 indexed citations
9.
Cohen, Steven J., Cornelis J.A. Punt, Nicholas Iannotti, et al.. (2008). Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 26(19). 3213–3221. 1473 indexed citations breakdown →
10.
Isharwal, Sumit, Michael Craig Miller, Jonathan I. Epstein, et al.. (2008). Prognostic value of Her‐2/neu and DNA index for progression, metastasis and prostate cancer‐specific death in men with long‐term follow‐up after radical prostatectomy. International Journal of Cancer. 123(11). 2636–2643. 21 indexed citations
11.
Moore, Richard G., Amy Brown, Michael Craig Miller, et al.. (2008). Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecologic Oncology. 110(2). 196–201. 182 indexed citations
12.
Veltri, Robert W., Sumit Isharwal, Michael Craig Miller, et al.. (2008). Long‐Term assessment of prostate cancer progression free survival: Evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis. The Prostate. 68(16). 1806–1815. 31 indexed citations
13.
Bono, Johann S. de, Howard I. Scher, Bruce Montgomery, et al.. (2008). Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 14(19). 6302–6309. 1744 indexed citations breakdown →
14.
Smirnov, Denis A., Daniel R. Zweitzig, Bradley W. Foulk, et al.. (2005). Global Gene Expression Profiling of Circulating Tumor Cells. Cancer Research. 65(12). 4993–4997. 268 indexed citations
15.
Miller, Michael Craig. (2005). Questions & answers. What is Type D personality?. PubMed. 22(5). 8–8. 1 indexed citations
16.
Allard, W. Jeffrey, Jeri Matera, Michael Craig Miller, et al.. (2004). Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases. Clinical Cancer Research. 10(20). 6897–6904. 2015 indexed citations breakdown →
17.
Miller, Michael Craig. (2004). Questions & answers. What is Symbyax, the new drug being marketed for the treatment of bipolar depression.. PubMed. 21(2). 8–8. 1 indexed citations
18.
Veltri, Robert W., Masood A. Khan, Michael Craig Miller, et al.. (2004). Ability to Predict Metastasis Based On Pathology Findings and Alterations in Nuclear Structure Of Normal-Appearing and Cancer Peripheral Zone Epithelium in the Prostate. Clinical Cancer Research. 10(10). 3465–3473. 44 indexed citations
19.
Orozco, Roberto, et al.. (1998). Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. Urology. 51(2). 186–195. 89 indexed citations
20.
Veltri, Robert W., Michael Craig Miller, Alan W. Partin, Donald S. Coffey, & Jonathan I. Epstein. (1996). Ability to predict biochemical progression using gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei. Urology. 48(5). 685–691. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tanja Fehm Breakdown of academic impact, for papers by W. Jeffrey Allard Breakdown of academic impact, for papers by Markus Wallwiener Breakdown of academic impact, for papers by Sara Y. Brucker Breakdown of academic impact, for papers by P. J. van Diest Breakdown of academic impact, for papers by Daphne W. Bell Breakdown of academic impact, for papers by Luis A. Díaz Breakdown of academic impact, for papers by Florin‐Andrei Taran Breakdown of academic impact, for papers by Eva‐Maria Grischke Breakdown of academic impact, for papers by Hitoshi Tsuda
Rankless by CCL
2026